Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.25 in the last session, down -0.79% from day before closing price of $1.26. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 0.63 million shares were traded.
Ratios:
We take a closer look at ZNTL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.94 and its Current Ratio is at 6.94. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.13.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.
Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.35 while its Price-to-Book (P/B) ratio in mrq is 0.30.
Stock Price History:
Over the past 52 weeks, ZNTL has reached a high of $13.00, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is -14.71%, while the 200-Day Moving Average is calculated to be -52.53%.
Shares Statistics:
A total of 71.95M shares are outstanding, with a floating share count of 55.63M. Insiders hold about 22.69% of the company’s shares, while institutions hold 74.29% stake in the company.
Earnings Estimates
The dynamic stock of Zentalis Pharmaceuticals Inc (ZNTL) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.4 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$1.78 and -$3.07 for the fiscal current year, implying an average EPS of -$2.21. EPS for the following year is -$2.05, with 9.0 analysts recommending between -$1.27 and -$3.27.
